Wuhan Starts Clinical Tests on Remdesivir, Will Release Test Results on April 27
Liao Shumin
DATE:  Feb 26 2020
/ SOURCE:  yicai
Wuhan Starts Clinical Tests on Remdesivir, Will Release Test Results on April 27 Wuhan Starts Clinical Tests on Remdesivir, Will Release Test Results on April 27

(Yicai Global) Feb. 25 -- US biopharmaceutical firm Gilead Sciences' Remdesivir has had good effects in curbing novel coronavirus pneumonia. Many Chinese hospitals in Wuhan have started clinical tests of the drug and will release their results on April 27, He Zhimin, deputy commissioner of China National Intellectual Property Administration, said today.

No country has yet approved Remdesivir's market entry, and it is still in the clinical test phase, He noted.

The pharmaceutical has been used to treat novel coronavirus patients in the US and France to good effect, however.

Gilead Sciences has applied for eight patents on the compound in China, with three of them already granted and the other five still under review, public data show. The scope of protection of these patents covers the drug's core structure and similar structures, manufacturing methods and usage.

After rounds of screening, the scientific research task-force has zeroed in on the antivirals Remdesivir, and the Favipiravir developed by Japan's Toyama Chemical, as well as the generic antimalarial Resochin first discovered by Bayer in 1924, and the group has conducted clinical trials of these drugs, Zhang Xinmin, director of China National Center for Biotechnology Development under the Ministry of Science and Technology, said on Feb. 15. Bedside tests of Remdesivir have involved 168 patients with severe symptoms and 17 with slight or moderate ones.

Editor: Ben Armour

Follow Yicai Global on
Keywords:   Novel Coronavirus Pneumonia